摘要
目的:观察益肺方联合化疗治疗晚期非小细胞肺癌的疗效和对治疗过程中产生的副反应改善情况。方法:收集符合纳入标准的住院患者80例,按入组先后时间排序,随机分为观察组和对照组,每组均为40例。对照组予单纯化疗,观察组在其基础上予益肺方口服治疗。4个治疗周期结束后评价2组治疗前后效果,并且记录治疗期间的不良反应。结果:在中医证候改善方面,观察组87.5%,高于对照组的62.5%;治疗后KPS评分分别为(82.05±5.06)和(73.78±5.27),观察组高于对照组;胃肠道反应发生率分别为35.0%和77.5%,白细胞减少发生率分别为15.0%和37.5%,观察组在治疗过程中出现的不良反应相对较少,差异均有统计学意义。观察组和对照组的实体瘤疗效评价疾病控制率分别为85.0%和80.0%,差异无统计学意义。结论:对于晚期非小细胞肺癌的患者,在化疗期间额外加服中药益肺方汤剂,有利于缓解患者的症状和减轻化疗药物的毒副反应,从而有效的提高患者生命质量。
Objective:To observe the efficacy and improvement of side reactions to the treatment process of Yifei formula combined with chemotherapy in advanced non-small cell lung cancer.Methods:a total of 80 hospitalized patients who met the inclusion criteria were collected,sorted according to the time of enrollment followed by time,and randomly divided into observation and control groups,40 in each group.The control group was given chemotherapy alone,and the observation group was given Yifei formula oral therapy on the basis of it.Before and after treatment effects in the 2 groups were evaluated after the end of 4 treatment cycles,and adverse effects during treatment were recorded.Results:in terms of TCM syndrome improvement,87.5%of the observation group was higher than 62.5%of the control group;The KPS scores after treatment were(82.05±5.06)and(73.78±5.27),respectively,higher in the observation group than in the control group;Gastrointestinal reactions occurred in 35.0%and 77.5%and leukopenia in 15.0%and 37.5%,respectively,and the observation group experienced relatively few adverse reactions during treatment,with statistically significant differences.Response evaluation of solid tumors in the observation and control groups the disease control rate was 85.0%and 80.0%,respectively,and the difference was not statistically significant.Conclusions:for patients with advanced non-small cell lung cancer,the additional administration of traditional Chinese medicine Yifei formula Decoction during chemotherapy is beneficial for relieving patients’symptoms and alleviating the toxic side effects of chemotherapeutic drugs,thus effectively improving patients’quality of life.
作者
王叶鹏
夏黎明
WANG Yepeng;XIA Liming(Anhui University of Chinese Medicine,Anhui Hefei 230038,China;The First Affiliated Hospital of Anhui University of Chinese Medicine,Anhui Hefei 230031,China)
出处
《中医药临床杂志》
2022年第10期1929-1932,共4页
Clinical Journal of Traditional Chinese Medicine
基金
安徽省教育厅2021年度安徽高校自然科学研究重点项目(KJ2021A0557)。
关键词
晚期非小细胞肺癌
益肺方
化疗
Advanced non-small cell lung cancer
Yifei Prescription
Chemotherapy